SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+29.68%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$236M
AUM Growth
+$236M
(+11%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
4.62%
Top 10 Holdings %
Top 10 Hldgs %
41.83%
Holding
92
New
24
Increased
26
Reduced
17
Closed
14
Top Buys
| 1 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
$7.67M |
| 2 |
Prothena Corp
PRTA
|
$6.67M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$6.51M |
| 4 |
VRAY
ViewRay, Inc.
VRAY
|
$5.79M |
| 5 |
Pliant Therapeutics
PLRX
|
$4.38M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$8.27M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$5.87M |
| 3 |
Biogen
BIIB
|
$4.25M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.13M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$3.84M |
Sector Composition
| 1 | Healthcare | 96.41% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLU
1
DELISTED
BELLUS Health Inc.
BLU
| $17.5M | 5.91% | 1,655,775 +92,818 | +6% | +$980K |
|
2
Veracyte
VCYT
$2.39B
| $11.1M | 3.74% | 665,854 -52,935 | -7% | -$879K |
|
3
Akero Therapeutics
AKRO
$3.74B
| $10.2M | 3.46% | 300,000 +39,675 | +15% | +$1.35M |
|
|
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $9.18M | 3.11% | 324,421 -94,239 | -23% | -$2.67M |
|
5
Cogent Biosciences
COGT
$1.69B
| $9.05M | 3.06% | 606,608 -214,346 | -26% | -$3.2M |
|
|
PSTX
6
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $9.02M | 3.05% | 2,554,277 +2,173,671 | +571% | +$7.67M |
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $8.88M | 3% | 245,992 +13,362 | +6% | +$482K |
|
8
Aclaris Therapeutics
ACRS
$209M
| $8.56M | 2.9% | 543,776 +4,231 | +0.8% | +$66.6K |
|
|
VRAY
9
DELISTED
ViewRay, Inc.
VRAY
| $8.46M | 2.86% | 2,324,066 +1,591,326 | +217% | +$5.79M |
|
10
Mersana Therapeutics
MRSN
$36.5M
| $6.72M | 2.27% | 994,073 +144,073 | +17% | +$974K |
|
|
11
Prothena Corp
PRTA
$441M
| $6.67M | 2.26% | +110,000 | New | +$6.67M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.51M | 2.2% | +32,545 | New | +$6.51M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.33M | 2.14% | 136,126 -177,836 | -57% | -$8.27M |
|
|
APEN
14
DELISTED
Apollo Endosurgery, Inc.
APEN
| $6.26M | 2.12% | 1,136,206 +61,327 | +6% | +$338K |
|
15
Merus
MRUS
$4.98B
| $5.91M | 2% | 295,136 -173,977 | -37% | -$3.49M |
|
16
Cerus
CERS
$251M
| $5.82M | 1.97% | 1,616,459 -477,402 | -23% | -$1.72M |
|
|
CTIC
17
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $5.72M | 1.94% | 983,516 -396,595 | -29% | -$2.31M |
|
18
Insmed
INSM
$28.8B
| $4.83M | 1.63% | 224,016 +11,534 | +5% | +$248K |
|
19
Nkarta
NKTX
$151M
| $4.77M | 1.61% | 362,377 +251,614 | +227% | +$3.31M |
|
|
20
Pliant Therapeutics
PLRX
$101M
| $4.38M | 1.48% | +209,822 | New | +$4.38M |
|
21
Acumen Pharmaceuticals
ABOS
$82.4M
| $4.21M | 1.43% | +420,000 | New | +$4.21M |
|
22
Krystal Biotech
KRYS
$4.27B
| $3.95M | 1.34% | 56,645 -48,632 | -46% | -$3.39M |
|
23
Oric Pharmaceuticals
ORIC
$994M
| $3.87M | 1.31% | 1,208,992 +126,688 | +12% | +$405K |
|
24
Vertex Pharmaceuticals
VRTX
$100B
| $3.22M | 1.09% | 11,105 +691 | +7% | +$200K |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.18M | 1.08% | +177,364 | New | +$3.18M |
|